CN1986814B - 血管抑制素与内皮抑制素在大肠杆菌中的融合表达产物及其制备方法 - Google Patents
血管抑制素与内皮抑制素在大肠杆菌中的融合表达产物及其制备方法 Download PDFInfo
- Publication number
- CN1986814B CN1986814B CN200510122594A CN200510122594A CN1986814B CN 1986814 B CN1986814 B CN 1986814B CN 200510122594 A CN200510122594 A CN 200510122594A CN 200510122594 A CN200510122594 A CN 200510122594A CN 1986814 B CN1986814 B CN 1986814B
- Authority
- CN
- China
- Prior art keywords
- endostatin
- angiostatin
- preparation
- expressed product
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000004927 fusion Effects 0.000 title claims abstract description 38
- 108010079505 Endostatins Proteins 0.000 title claims description 50
- 238000000034 method Methods 0.000 title claims description 12
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 title abstract 5
- 230000002792 vascular Effects 0.000 title abstract 5
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims abstract description 24
- 238000006243 chemical reaction Methods 0.000 claims abstract description 21
- 238000012408 PCR amplification Methods 0.000 claims abstract description 8
- 238000010839 reverse transcription Methods 0.000 claims abstract description 5
- 241001465754 Metazoa Species 0.000 claims abstract description 3
- 210000005228 liver tissue Anatomy 0.000 claims abstract description 3
- 108010079709 Angiostatins Proteins 0.000 claims description 51
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims description 48
- 102400001047 Endostatin Human genes 0.000 claims description 38
- 241000894006 Bacteria Species 0.000 claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 32
- 239000000047 product Substances 0.000 claims description 29
- 239000000243 solution Substances 0.000 claims description 25
- 239000006228 supernatant Substances 0.000 claims description 23
- 239000007788 liquid Substances 0.000 claims description 20
- 239000013612 plasmid Substances 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 14
- 238000003259 recombinant expression Methods 0.000 claims description 14
- 108091008146 restriction endonucleases Proteins 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 12
- 235000015097 nutrients Nutrition 0.000 claims description 12
- 238000001556 precipitation Methods 0.000 claims description 12
- 239000013613 expression plasmid Substances 0.000 claims description 10
- 230000003321 amplification Effects 0.000 claims description 8
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 230000000968 intestinal effect Effects 0.000 claims description 7
- 238000011144 upstream manufacturing Methods 0.000 claims description 6
- 230000029087 digestion Effects 0.000 claims description 5
- 238000004153 renaturation Methods 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 229920000936 Agarose Polymers 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 4
- 238000013016 damping Methods 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 229960002897 heparin Drugs 0.000 claims description 4
- 229920000669 heparin Polymers 0.000 claims description 4
- 238000012546 transfer Methods 0.000 claims description 4
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 3
- 229920001817 Agar Polymers 0.000 claims description 3
- 241000672609 Escherichia coli BL21 Species 0.000 claims description 3
- 102000003960 Ligases Human genes 0.000 claims description 3
- 108090000364 Ligases Proteins 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 239000012149 elution buffer Substances 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 238000011081 inoculation Methods 0.000 claims description 3
- XUWPJKDMEZSVTP-LTYMHZPRSA-N kalafungina Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1[C@@H](C)O[C@H]1[C@@H]2OC(=O)C1 XUWPJKDMEZSVTP-LTYMHZPRSA-N 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 102400000068 Angiostatin Human genes 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 abstract description 4
- 238000000605 extraction Methods 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 2
- 238000003776 cleavage reaction Methods 0.000 abstract 2
- 230000007017 scission Effects 0.000 abstract 2
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 102000012936 Angiostatins Human genes 0.000 description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 12
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 210000003000 inclusion body Anatomy 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 210000000998 shell membrane Anatomy 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 210000001136 chorion Anatomy 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004862 vasculogenesis Effects 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000001935 peptisation Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510122594A CN1986814B (zh) | 2005-12-23 | 2005-12-23 | 血管抑制素与内皮抑制素在大肠杆菌中的融合表达产物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510122594A CN1986814B (zh) | 2005-12-23 | 2005-12-23 | 血管抑制素与内皮抑制素在大肠杆菌中的融合表达产物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1986814A CN1986814A (zh) | 2007-06-27 |
CN1986814B true CN1986814B (zh) | 2010-05-05 |
Family
ID=38183758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200510122594A Active CN1986814B (zh) | 2005-12-23 | 2005-12-23 | 血管抑制素与内皮抑制素在大肠杆菌中的融合表达产物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1986814B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101768219B (zh) * | 2008-12-30 | 2012-11-21 | 江苏先声药物研究有限公司 | 一种重组融合蛋白及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1224758A (zh) * | 1998-09-25 | 1999-08-04 | 中山大学 | 人血管生成抑制素基因、含有该基因的载体和菌株及其表达产物的生产和应用 |
CN1397642A (zh) * | 2002-08-16 | 2003-02-19 | 无锡博生医用生物技术开发有限公司 | 携带抗血管和抗内皮细胞因子融合基因的重组疱疹病毒 |
US20050175591A1 (en) * | 2004-01-28 | 2005-08-11 | Research Development Foundation | Human soluble neuropilin-1 primary polyadenylation signal and uses thereof |
-
2005
- 2005-12-23 CN CN200510122594A patent/CN1986814B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1224758A (zh) * | 1998-09-25 | 1999-08-04 | 中山大学 | 人血管生成抑制素基因、含有该基因的载体和菌株及其表达产物的生产和应用 |
CN1397642A (zh) * | 2002-08-16 | 2003-02-19 | 无锡博生医用生物技术开发有限公司 | 携带抗血管和抗内皮细胞因子融合基因的重组疱疹病毒 |
US20050175591A1 (en) * | 2004-01-28 | 2005-08-11 | Research Development Foundation | Human soluble neuropilin-1 primary polyadenylation signal and uses thereof |
Non-Patent Citations (4)
Title |
---|
Frank A. Scappaticci et al..Statin-AE: Anovel angiostatin-endostatin fusion protein withenhanced antiangiogenic and antiumor activity.Angiogenesis4.2001,4263-268. |
Frank A.Scappaticci et al..Statin-AE: Anovel angiostatin-endostatin fusion protein withenhanced antiangiogenic and antiumor activity.Angiogenesis4.2001,4263-268. * |
毛晓燕,李仁德,梁国栋.血管抑制素和内皮抑制素的协同作用.医学分子生物学杂志2 1.2005,2(1),49-52. |
毛晓燕,李仁德,梁国栋.血管抑制素和内皮抑制素的协同作用.医学分子生物学杂志2 1.2005,2(1),49-52. * |
Also Published As
Publication number | Publication date |
---|---|
CN1986814A (zh) | 2007-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108159409A (zh) | 一种猪圆环病毒3型Cap蛋白疫苗及其制备方法和应用 | |
CN111393531A (zh) | 一种亚单位融合蛋白CD2V-Fc及其制备方法和应用 | |
CN113512096B (zh) | 一种鲈鱼弹状病毒重组g2蛋白及其应用 | |
CN102735680A (zh) | 一种猪圆环病毒2型抗体胶体金快速检测试纸条 | |
CN102816246B (zh) | 一种人巨细胞病毒免疫原融合蛋白及其制备方法和用途 | |
CN109593693A (zh) | 一株大肠杆菌Nissle 1917抗肿瘤靶向工程菌及其构建方法与应用 | |
CN109053904A (zh) | Appv-e2融合蛋白及其制备方法、应用和疫苗 | |
CN111187353A (zh) | 一种高效表达PCV2 Cap、PCV3 Cap融合蛋白的方法 | |
CN107488234A (zh) | 禽腺病毒Hexon与鸡传染性法氏囊病病毒VP2融合抗原、亚单位疫苗及其制备方法 | |
CN104611299A (zh) | 一种人工重组的h9n2禽流感病毒株、制备方法、疫苗组合物及其应用 | |
CN1986814B (zh) | 血管抑制素与内皮抑制素在大肠杆菌中的融合表达产物及其制备方法 | |
CN106754981B (zh) | 一种利用大肠杆菌系统制备小鹅瘟病毒样颗粒的方法 | |
CN104744595B (zh) | 抗草鱼出血病病毒工程蛋白tat‑vp7‑tat及制备方法和应用 | |
CN101353668B (zh) | 鼠β-防御素1的重组质粒、多肽及其用途与制备方法 | |
CN102604993A (zh) | 免疫佐剂与幽门螺杆菌抗原融合蛋白口服疫苗及其制备方法 | |
CN109180821A (zh) | 鸡新城疫病毒的融合蛋白及其制备方法、应用和疫苗 | |
CN115010812A (zh) | 一种非洲猪瘟抗原介导细胞免疫的多聚体及应用 | |
CN103861094A (zh) | 一种产气荚膜梭菌α毒素基因工程疫苗及其应用 | |
CN102199608B (zh) | 家蚕反应器高效表达三叶半夏凝集素 | |
CN105418767A (zh) | 一种用于制备Aβ表位疫苗的融合蛋白及其制备方法和用途 | |
CN110257414A (zh) | 一种小鼠MIP3α-endoglin Fc融合蛋白的制备方法及其用途 | |
CN105505943A (zh) | 一种妊娠特异性糖蛋白3标准品、其制备方法以及用于制备的重组菌 | |
CN109180820A (zh) | 马流感病毒h3n8亚型的融合蛋白及其制备方法、应用和疫苗 | |
CN113980146B (zh) | 三聚体化鸭黄病毒E蛋白domainIII、其制备方法和运用 | |
CN102935227A (zh) | 鸡新城疫病毒hn基因亚单位疫苗及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: TIANJIN JINSITAN BIOLOGICAL TECHNOLOGY CO.,LTD. Free format text: FORMER OWNER: WANG WEIXING Effective date: 20130913 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 300191 NANKAI, TIANJIN TO: 300000 BINHAI NEW ZONE, TIANJIN CITY |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130913 Address after: 300000 Tianjin Huayuan Industrial Park (outer ring) six J 101 hi tech Development Patentee after: Tianjin Jinsitan Biological Technology Co.,Ltd. Address before: 300191 1 gates, 6 buildings, 49 Nankai District Water Park Road, Tianjin Patentee before: Wang Weixing |